Pfizer and BioNTech Celebrate Historic First Authorization in the US of Vaccine to Prevent COVID-19,

The ongoing Phase 3 clinical trial of BNT162b2, which is based on BioNTech’s proprietary mRNA technology, has enrolled more than 44,000 …, The ongoing Phase 3 clinical trial of BNT162b2, which is based on BioNTech’s proprietary mRNA technology, has enrolled more than 44,000 …, Read More

Scroll to Top